CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
The selling pressure continued on Wednesday with the S&P/ASX 200 (ASX: XJO) falling 0.8% as uncertainty around the world continues to grow.
The S&P/ASX 200 (ASX:XJO) finished down 0.6% on Friday as Paladin Energy (ASX:PDN) and CSL (ASX:CSL) shares were in the news.
Cathie Wood’s ARK Genomic Revolution ETF (BATS: ARKG) and ASX-listed biotech stocks have been beaten up mercilessly, so is now the time to buy?
The Nanosonics Ltd (ASX: NAN) share price is sinking despite announcing a 41% bump in revenue for the first-half of FY22.
ASX shares have been releasing some monster earnings in week 2 of the February reporting season. Here’s your recap of all the big movements.
Surges from CSL Limited (ASX:CSL) and BHP Group Ltd (ASX:BHP) shares powered the S&P/ASX 200 (ASX:XJO) to a three-week high on Thursday
Healthy earnings results from the likes of CSL (ASX:CSL) and Treasury Wine (ASX:TWE) helped push the ASX 200 (ASX:XJO) higher on Wednesday.
The CSL Limited (ASX: CSL) share price has stormed out of the gates this morning up 6% after announcing its first-half results.
Your guide to the BHP Group Ltd (ASX:BHP) reunification process and what it means for your shareholding, the ASX and exchange traded funds.
